SI-BONE, Inc. (SIBN) Sentiment Analysis

SI-BONE, Inc. (SIBN) has an ST Score of 68.4 (B+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate SIBN a Buy, with a price target of $23.00 (+12.0% vs the current price). Our ST Score grades it B+ (68.4/100). The ST Score is a data-driven signal, not a recommendation.

Valuation B, Profitability A-, Financial Strength B+, Momentum A, Growth B+, Forecast B-.

SI-BONE, Inc. (SIBN) earns a valuation grade of B, measured against Medical - Devices peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

SI-BONE, Inc. (SIBN) earns a growth grade of B+, measured against Medical - Devices peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

SI-BONE, Inc. (SIBN) earns a profitability grade of A-, measured against Medical - Devices peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

SI-BONE, Inc. (SIBN) earns a financial strength grade of B+, measured against Medical - Devices peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for SI-BONE, Inc. (SIBN) is $23.00 from 10 analysts, which is +12.0% versus the recent price of $20.54.

SI-BONE, Inc. (SIBN) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.